Neuropeptide Y (NPY) is thought to be co-released with catecholamines in response to
major cardiovascular stresses, but its relation to the release of catecholamines in response …

Publisher Summary This chapter focuses on the attempts to further characterize the
relationship of NPY to NE release under physiological and pathophysiological conditions …

Stress is known as a major risk factor for cardiovascular morbidity and mortality since the
novel cardiac syndrome tako-tsubo cardiomyopathy, also known as stress cardiomyopathy …

Neuropeptide-Y (NPY) is a sympathetic cotransmitter, which causes vasoconstriction,
decreases coronary blood flow and decreases cardiac output. Circulating immunoreactive …

Neuropeptide Y (NPY), a putative sympathetic neurotransmitter and neuromodulator, is
released during sympathetic nerve stimulation and causes vasoconstriction and …

Abstract purpose: Our objectives were to assess whether plasma neuropeptide Y (NPY)
levels are elevated in patients with congestive heart failure (CHF) and whether or not NPY …

Plasma neuropeptide Y (NPY) was measured by radioimmunoassay in 43 patients with
congestive heart failure (CHF) and 20 healthy control subjects. The results showed that …

Neuropeptide Y (NPY) is co-released with noradrenaline from sympathetic nerves, has a
strong vasoconstrictive action, and causes an attenuation of parasympathetic action in …

The relationship among neuropeptide Y (NPY), catecholamines and haemodynamics was
assessed both at baseline and during inotropic intervention in patients with congestive heart …

Madsen BK, Husum D., Videbaek R., Stokholm KH, Saslsen L., Christensen NJ Plasma
immunoreactive Neuropeptide Y in congestive heart failure at rest and during exercise …